Preexposure Prophylaxis Indication Criteria Underidentify Black and Latinx Persons and Require Revision

Aaron J. Siegler, PhD

Disclosures

Am J Public Health. 2020;110(3):267-268. 

In This Article

Conclusions

Pyra et al. note that their work extends arguments regarding the insufficiency of current PrEP indication guidance and emphasize that improving access should not contribute to any further stigmatization. It is noteworthy that the CDC conducted some of the initial PrEP trials and provided some of the earliest guidance regarding PrEP. The US Food and Drug Administration was one of the first bodies to approve a medication for PrEP. This type of leadership is encouraging and merits confidence that current challenges with PrEP indication guidance are likely to be addressed in short order. Recently, the CDC predicted that in the absence of intervention 1 in 2 Black MSM, 1 in 5 Latinx MSM, and 1 in 11 White MSM will acquire HIV in their lifetimes. Given the high safety and efficacy of PrEP, it is hard to justify communication with any member of these groups that would not support PrEP use.

processing....